Medivir to present at Redeye Growth Day
Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announces that the company will participate at Redeye Growth Day, today May 30, 2024. CEO Jens Lindberg will present updated data from the ongoing phase 1b/2a clinical study with fostroxacitabine bralpamide (fostrox) and the development plans moving forward at 09.40 CET. The presentation is live broadcasted and can be followed at the event page, where the replay and the presentations will be available